CAR-T cost per patient should decrease when safety increases the footprint of patients who can be safely treated. That efficiency of a larger treatable patient population also goes for other immunotherapies, like the anti-PDxx variety.
Bavituximab provides that safety. Dr. Brekken of UTSW clearly stated that he saw a 200% to 300% increased response rate footprint where bavi was combined with other immunotherapies. That means increased efficacy and safety.
Market Data 
Markets 
AI
